News
6-year data from the ECHELON-1 study: How does combining brentuximab vedotin with chemotherapy affect overall survival of previously untreated cHL patients?
At this year's annual congress of the European Hematology Association (EHA), results from the analysis of 6-year data from the international randomized open-label phase III ECHELON-1 study on overall survival of patients with classical Hodgkin lymphoma (cHL) stage III/IV who received a combination of brentuximab vedotin with chemotherapy in the first-line treatment were presented, among other findings.
How to Save a Leg from Amputation?
Feared complications in diabetics include defects in typical locations on the lower limbs. Their…
Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results
A freshly published real-world clinical practice study from Spain highlights the experience of…
Benefit of Adding Empagliflozin to Standard Therapy in Heart Failure with Reduced Ejection Fraction
The use of empagliflozin led to a reduction in the risk of hospitalization for heart failure or…
Sequential administration of immunochemotherapy and venetoclax after failure of BCR inhibitor treatment – interactive video case study
The treatment of chronic lymphocytic leukemia (CLL) is evolving. What was impossible years ago is…
Hydroresponsive Dressings for Acute and Hard-to-Heal Wounds
A recently published review of clinical evidence from nearly three dozen studies demonstrates…
Prediabetes through the lens of current data and findings − and why hurry with intervention
Type 2 diabetes mellitus (DM2) is one of the most common causes of premature morbidity and…
Discontinuation of Methotrexate After Initiation of Tofacitinib in the Treatment of Rheumatoid Arthritis
New real-world data show that in patients with rheumatoid arthritis (RA) who started treatment with…
Incidence of CV Events, Malignancies, and Venous Thromboembolism in Patients with RA According to Baseline CV Risk and Administered Treatment
An international team of experts evaluated the impact of cardiovascular (CV) risk on the incidence…
Increase in Hematocrit During Empagliflozin Treatment in a Diabetic Patient with Severe Anemia − A Case Study
In a case study involving a 78-year-old diabetic patient, where only the administration of…
Conferences
News from the world of medicine
11. 6.
All conferences
Popular this week
- Intermittent Fasting May Carry Significant Health Risks
- Tuberous Sclerosis
- Multiple system atrophy
- How Compassion Fatigue Threatens Doctors and Other Healthcare Workers
- BENIGN DERMATOSIS OF PENIS